Daewoong Co., Ltd. (KRX:003090)
24,400
+150 (0.62%)
At close: Sep 5, 2025
Daewoong Revenue
Daewoong had revenue of 528.43B KRW in the quarter ending June 30, 2025, with 11.65% growth. This brings the company's revenue in the last twelve months to 2.03T, up 11.17% year-over-year. In the year 2024, Daewoong had annual revenue of 1.94T with 6.79% growth.
Revenue (ttm)
2,029.63B
Revenue Growth
+11.17%
P/S Ratio
0.49
Revenue / Employee
5.36B
Employees
379
Market Cap
985.47B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,936.92B | 123.08B | 6.79% |
Dec 31, 2023 | 1,813.84B | 116.50B | 6.86% |
Dec 31, 2022 | 1,697.34B | 185.96B | 12.30% |
Dec 31, 2021 | 1,511.37B | 156.04B | 11.51% |
Dec 31, 2020 | 1,355.34B | -10.34B | -0.76% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
ABL Bio | 94.93B |